These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 1583298

  • 21. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
    Shimizu A, Ookubo K, Hasegawa J, Endoh T, Fujiwara O, Yoda A, Okuyama D, Narabayashi A, Kimura T, Takahashi J, Notake Y.
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
    [Abstract] [Full Text] [Related]

  • 22. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
    Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B.
    Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
    [Abstract] [Full Text] [Related]

  • 23. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS.
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [Abstract] [Full Text] [Related]

  • 24. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.
    De Placido S, Tramontana S, Ferrari E, De Matteis A, Lauria R, Perrone F, Bianco AR, Gallo C, Ricchi P, De Placido G, Pignata S, GCTO (Gruppo Campano Sui Tumori Dell'Ovaio).
    Anticancer Res; 2000 Dec; 20(5C):4023-9. PubMed ID: 11268496
    [Abstract] [Full Text] [Related]

  • 25. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H.
    Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
    [Abstract] [Full Text] [Related]

  • 26. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS.
    Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
    [Abstract] [Full Text] [Related]

  • 27. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Apr; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 28. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T, Klasa-Mazurkiewicz D, Emerich J, Kobierski J.
    Acta Obstet Gynecol Scand; 2009 Apr; 88(4):463-7. PubMed ID: 19235559
    [Abstract] [Full Text] [Related]

  • 29. [Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin].
    Nakagawa H, Miyawaki Y, Tokiyoshi K, Tsuruzono K, Yamada M, Kanayama T, Hayakawa T.
    No Shinkei Geka; 1994 Jan; 22(1):35-42. PubMed ID: 8295700
    [Abstract] [Full Text] [Related]

  • 30. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S.
    Anticancer Res; 2005 Jan; 25(5):3501-5. PubMed ID: 16101169
    [Abstract] [Full Text] [Related]

  • 31. [Intraperitoneal chemotherapy of CDDP and etoposide in patients with advanced ovarian cancer].
    Hirashima Y, Shimura T, Tanaka Y, Demukai H, Kubota T, Kobayashi T, Suzuki A.
    Gan To Kagaku Ryoho; 1993 Aug; 20(10):1321-6. PubMed ID: 8346930
    [Abstract] [Full Text] [Related]

  • 32. [Intraperitoneal cisplatin chemotherapy for ovarian cancer].
    Hayashi H, Nishii H, Ueda K, Kunitou S, Wada S, Takanashi H, Kobayashi S, Yasuda M.
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2043-8. PubMed ID: 11791382
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Nursing procedures for intraperitoneal administration of cis-platin and Ara-C in the community hospital.
    Olson EZ, Selders NJ.
    Prog Clin Biol Res; 1986 Dec; 216():367-75. PubMed ID: 3725800
    [No Abstract] [Full Text] [Related]

  • 36. [Chemotherapy in malignant gynecologic tumors using intraperitoneal catheter with a subcutaneous reservoir].
    Shimizu A, Kimura T, Funatsu M, Hada Y, Araki H, Notake Y.
    Gan To Kagaku Ryoho; 1991 Aug; 18(11):1795-9. PubMed ID: 1877820
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer.
    Esposito M, Campora E, Repetto M, Fulco RA, Simoni GA, Falcone A, Collecchi P, Gogioso L, Nobile MT, Civalleri D.
    Oncology; 1988 Aug; 45(2):69-73. PubMed ID: 3353075
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Characterization of transplant generations of primary rat adenocarcinoma and some chemotherapeutic observations.
    Sugiyama T, Nishida T, Nakanami M, Ushijima K, Shibue K, Katabuchi H, Yakushiji M, Kato T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1987 Apr; 39(4):681-6. PubMed ID: 3108423
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.